Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma

Virology

Volumn 441, Issue 2, 2013, Pages 107-113

  Fogg, Mark ^a   Murphy, John R ^c   Lorch, Jochen ^b   Posner, Marshall ^b,d   Wang, Fred ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; Epstein Barr virus; Nasopharyngeal carcinoma; Ontak; T regulatory cells

Indexed keywords

DENILEUKIN DIFTITOX; EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 2;

ARTICLE; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION;

CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HUMANS; IMMUNE TOLERANCE; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, REGULATORY; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84877920105     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.03.016     Document Type: Article

References (27)

1. Blake N., Haigh T., Shaka'a G., Croom-Carter D., Rickinson A. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 2000, 165:7078-7087.
2. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., Nelson D.R. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40:1062-1071.
3. Deacon E.M., Pallesen G., Niedobitek G., Crocker J., Brooks L., Rickinson A.B., Young L.S. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 1993, 177:339-349.
4. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., Heslop H.E., Brenner M.K., Dotti G., Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
5. Fogg M.H., Wirth L.J., Posner M., Wang F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc. Nat. Acad. Sci. USA 2009, 106:3318-3323.
6. Herait P., Ganem G., Lipinski M., Carlu C., Micheau C., Schwaab G., De-The G., Tursz T. Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells. Br. J. Cancer 1987, 55:135-139.
7. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25:587-617.
8. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., Le Moulec S., Guigay J., Hirashima M., Guemira F., et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
9. Lau K.M., Cheng S.H., Lo K.W., Lee S.A., Woo J.K., van Hasselt C.A., Lee S.P., Rickinson A.B., Ng M.H. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br. J. Cancer 2007, 96:617-622.
10. Li J., Chen Q.Y., Mo H., Zhang Y.L., Huang Z.F., Zeng Y.X. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy. Int. J. Biol. Sci. 2011, 7:607-617.
11. Li J., Huang Z.F., Xiong G., Mo H.Y., Qiu F., Mai H.Q., Chen Q.Y., He J., Chen S.P., Zheng L.M., et al. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma. J. Transl. Med. 2011, 9:189.
12. Louis C.U., Straathof K., Bollard C.M., Gerken C., Huls M.H., Gresik M.V., Wu M.F., Weiss H.L., Gee A.P., Brenner M.K., et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113:2442-2450.
13. Mahnke K., Schonfeld K., Fondel S., Ring S., Karakhanova S., Wiedemeyer K., Bedke T., Johnson T.S., Storn V., Schallenberg S., Enk A.H. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120:2723-2733.
14. Marshall N.A., Vickers M.A., Barker R.N. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J. Immunol. 2003, 170:6183-6189.
15. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., Vickers M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
16. Miller G., Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Nat. Acad. Sci. USA 1973, 70:190-194.
17. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., Clay T.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
18. Moss D.J., Chan S.H., Burrows S.R., Chew T.S., Kane R.G., Staples J.A., Kunaratnam N. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int. J. Cancer 1983, 32:301-305.
19. Murray P.G., Niedobitek G., Kremmer E., Grasser F., Reynolds G.M., Cruchley A., Williams D.M., Muller-Lantzsch N., Young L.S. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J. Pathol. 1996, 178:44-47.
20. Niedobitek G., Young L.S., Sam C.K., Brooks L., Prasad U., Rickinson A.B Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am. J. Pathol. 1992, 140:879-887.
21. Reed L.J., Muench H. A simple method of estimating fity percent end-points. Am. J. Hyg. 1938, 27:493-497.
22. Rickinson A., Kieff E. Epstein-Barr Virus. Fields Virology 2007, vol. 2:2655-2700. Lippincott Williams and Wilkins, Philadelphia. 5th edition.
23. Smith C., Tsang J., Beagley L., Chua D., Lee V., Li V., Moss D.J., Coman W., Chan K.H., Nicholls J., et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012, 72:1116-1125.
24. Straathof K.C., Bollard C.M., Popat U., Huls M.H., Lopez T., Morriss M.C., Gresik M.V., Gee A.P., Russell H.V., Brenner M.K., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005, 105:1898-1904.
25. Voo K.S., Peng G., Guo Z., Fu T., Li Y., Frappier L., Wang R.F. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 2005, 65:1577-1586.
26. Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990, 265:11885-11889.
27. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., Zhao J.M., Zhang B., Shi M., Ding X., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 2006, 177:739-747.